Eli Lilly’s recent success largely centers on the impressive sales of two drugs, Mounjaro and Zepbound, both of which target the highly lucrative diabetes and weight-loss markets. Approved for diabetes in 2022, Mounjaro quickly became a blockbuster, with revenues reaching $3.09 billion in Q2 2024 alone—triple the amount from the same quarter the previous year. Zepbound, approved for obesity in late 2023, also demonstrated strong sales, adding more than $1 billion in U.S. revenue within its first year on the market
The explosive sales from these two drugs pushed Eli Lilly to significantly raise its revenue guidance for 2024, now expecting between $45.4 billion and $46.6 billion, up by $3 billion from prior estimates. The company’s stock has soared nearly 50% since the start of the year, and it’s now edging close to a $1 trillion market valuation, positioning it among the world’s most valuable pharmaceutical companies
Indianapolis Business Journal.
This growth trend highlights Eli Lilly’s effective capture of the diabetes and weight-management sectors, which continue to expand, with the global weight-loss market expected to reach $105–144 billion by 2030. This momentum has strengthened Lilly’s reputation in the healthcare industry, solidifying its role as a leader in innovative drug solutions and its influence on future market dynamics.
Author: Ryan Mullin
I Love the city of Indianapolis. Art, real estate, small biz and model trains. :)